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Objective: The aim of the present investigation was to determine
the level of the active form of the endogenous protein Anti-
secretory Factor (actAF), and also the active form of AF immuno-
reactive molecules in the afﬁnity puriﬁed egg yolk.
Design: Determination of AF in afﬁnity puriﬁed egg yolk by means
of in vivo and in vitro methods.
Setting: Sahlgrenska University Hospital and Chalmers University
of Technology, both units located in Gothenburg, Sweden. The farm
housing the egg-laying hens is situated some 10 miles west to
Stockholm.
Samples: Egg yolk collected weekly from hens subjected to AF-
stimulating feed for up to 18 weeks.
Methods and main outcome measures: The methods used were:
a/ The in vivo rat ligated jejunal loop assay.
b/ Two variations of ELISA, i.e.
1. An indirect ELISA using a polyclonal antibody against AF-16
antibodies.
2. A competitive enzyme immunoassay for detection of the
peptide AF-16 and also related immunoreactive molecules.
c/ Matrix-Assisted Laser Desorption Ionization Mass Spec-
trometry, (MALDI-MS).
The numeric variables registered represents:berg).
r Ltd onbehalf ofEuropeanSociety for ClinicalNutritionandMetabolism. This is
e (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of AF on the in vivo secretory response (mg/cm) to cholera
toxin challenge. The ligated loop is some 12e15 cm long and
placed on the mid part of jejunum, and the cholera toxin
induced secretion is registered after a 5 h long challenge
period.
b/ The indirect ELISA method demonstrates the relative con-
centration of immunogenic AF peptides/AF-16 peptides and
also related immunoreactive compounds by means of absor-
bance values, while the values of the competitive immunoassay
represent the concentration of AF-16 peptides including similar
immunoreactive peptides in ng/ml.
c/ The MALDI-MS method provide information about the
concentration of the AF-16 peptide down to nanogram per ml.
levels after mass spectrometry analysis of the sample.
Results: All methods revealed similar results by demonstrating a
continuous increase over time in the collected egg yolk samples.
Thus, low AF activity was registered in egg yolk collected in the
period of 1e10 weeks of AF-stimulated feeding, signiﬁcantly
higher AF values was registered in yolk collected between 10 and
15 weeks of feeding, while maximal AF concentration was deter-
mined after 15 weeks of feeding. Thus, in the period between 15
and 18 weeks of stimulated AF-feeding, no further increase of the
endogenous AF activity could be registered despite continuous AF-
stimulated feeding.
Conclusion: During the period of AF-stimulated feeding of the egg
laying hens the registration of AF concentration in the afﬁnity
puriﬁed egg yolk samples must be continuously registered over
time. The various methods used for determination of AF concen-
tration in the afﬁnity puriﬁed egg yolk might all serve as tools in
order to achieve the optimal concentration of active AF. Together,
these methods will provide information about the optimal AF
concentration in the ﬁnal product consisting of spray dried egg
yolk (Salovum®) used for disease treatment.
© 2017 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Antisecretory Factor (AF) also designated S5a, is a ubiquitous occurring endogenous protein
demonstrated in all tissues so far analyzed [1,2]. In vivo AF acts as a regulator of water and ion transport
across the cellular membrane and also mediates anti-inﬂammatory effects [3e8]. AF mode of action
in vivo is intimately connected to the action of the complement system, forming complexes with C3 as
well as with C4 [9]. AF is a constituent of the 19S proteasome subunit and can be considered as a part of
the innate host defense system [9]. AF is present in blood in an active (actAF) form as well as in an
inactive (AF) form [10]. AF is transformed into an active from after exposure of the small intestine to
bacterial toxins or after intake of certain dietary products e.g. specially processed cereals (SPC-Flakes)
[11,12]. The detailed biological action behind this activating mechanisms remains to be described, but
probably actAF is the ﬁnal product of a process which include exposure of the AF peptide after binding
between the proteasome and the complement [9]. The active part of the full length AF protein, i.e. the
part of the protein regulating the process behind secretion and inﬂammation, is located in the amino
terminal part [13]. Various peptides emanating from amino acids sequences in this part of the AF
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of these peptides, the synthetic produced AF-16 peptide, made up of amino acids 36e51 of the full
length AF protein, has been demonstrated to be the most preferable to use in experimental work, and
consequently also to analyze in vivo and in vitro.
Salovum is a spray dried egg yolk rich in AF peptides, achieved after feeding the hens with an
AF-inducing feed. The clinical useof theAF concept in the formof Salovumadministrationhasbeen tested
in controlled, clinical studies with patients suffering from diarrheal diseases [8,14,15], mastitis [16], Mb
Crohn [7], colitis ulcerosa [14] and Meniere's disease [17]. In the studies performed so far, the regulating
effects of actAF on secretion and inﬂammation have been demonstrated to signiﬁcantly improve the
clinical outcomeof thevariousdiseases. Furthermore, a raised intracranial pressure, commonly registered
after various forms of trauma to the scull, can also be signiﬁcantly counteracted and suppressed to normal
levels in response to intake of Salovum [12]. The clinical inﬂuence of Salovum on the secretory and the
inﬂammatoryprocesses suggests a general,modulatingeffect ofactAF in theﬁrst handonneuronal tissue,
but also on intestinal tissue [18]. Furthermore, improvement of the clinical outcome in the diseased
patient in response to Salovum intake demonstrates a need for registrationmethods of AF concentration
in Salovum. The validity of suchmethods is ofmajor relevance for a regulated patient treatment, in order
to ensure optimal and reproducible effects on the clinical outcome over time.
Thus, an improved clinical outcome has been registered in response to Salovum treatment of
patients suffering from various diseases. Consequently, it is of importance to relate concentrations of
AF-peptides in the egg yolk to the clinical effects achieved and registered.
The aim of this study was to analyze in vivo by the rat ligated loop assay the level of active AF in the
afﬁnity puriﬁed egg yolk [19]. The values of AF levels determined by this basic in vivo method for
anti-secretory activity should thereafter be compared to the AF values achieved by the three in vitro
methods described.
Consequently, in order to achieve reproducible and accurate clinical effects on pathophysiological
variables in relation to Salovum intake, the AF concentration in the egg yolk must be determined in
each one of the Salovum batches produced.
2. Material and methods
2.1. Animals
The test protocol was approved by the Regional Animal Experiments Ethical Committee in Goth-
enburg. All experiments were performed in accordance to guidelines for animal experiments (EC
Directive 86/609/EEC). At arrival the male SpragueeDawley rats (Nova-SCB, Sollentuna, Sweden)
displayed a body weight of 180 ± 20 g. All rats were allowed a week for general adaptation in their
cages before any form of experimental procedure started. The temperature and air ventilation in the
animal quarters were monitored according to standard procedures.
2.2. Preparation of active AF from egg yolk
Egg-laying hens were fed an AF-stimulating diet, achieved by addition of specially processed cereals
(SPC) to the ordinary hen feed. The special processing means a hydrothermal treatment of the cereals
which changes the content of sugars and amino acids within deﬁned limits. This speciﬁc alteration of
sugars and amino acids in the AF-stimulating cereals has been described in detail previously [5].
The eggs were collected once a week and stored at þ4 C. The egg yolk was afﬁnity puriﬁed before
in vivo or in vitro determination of AF. AF was puriﬁed from egg yolk by afﬁnity chromatography as
previously described for human plasma [5]. The afﬁnity puriﬁcation process started by dissolving four
yolks in phosphate buffered saline (sodium chloride, 145 mmol/l, buffered to pH 7.1 with 70 mmol/l
phosphate, PBS), followed by centrifugation at 1000 g for 5 min, where after the supernatant was
collected and passed through a 3 ml agarose column (Sepharose 6B, GE Healthcare Biosciences AB). This
process results in bindingof the activeAF to the agarose. PBSwashingof the column followed,where after
the agarose-absorbedAFwas eluted from the agarose by passage of 1Ma-methyl-D-glycoside. The eluate
was dialyzed against PBS for 24 h at þ4 C and thereafter stored at 20 C until use.
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The test performed for determination of the total, active AF content, was done in vivo by means of
the rat ligated loop assay using cholera toxin (CT) as the secretagogue [20]. Thus, the puriﬁed egg yolk
samples were injected intravenously into the anaesthetized rat. CT challenge (1.5 ml) in the 12e15 long
jejunal loop followed, where after the total, secreted volume in response to the toxin was registered
after a 5 h long challenge period.
An AF preparation mediating a 50% inhibition of the CT-induced ﬂuid secretion was assigned one
“AF-unit” value of 0.5. Previous experimental diarrheal studies have shown that AF values >0.5 AF units
are correlated to a signiﬁcant, clinical reduction of diarrhea in man as well as in animals [5,21].
2.4. AF-16 polyclonal antibody
Rabbits were used for production of primary polyclonal antibody against the AF peptide 36-
VCHSKTRSNPENNVGL-51 (aP8, Innovagen AB, Lund, Sweden). The peptide was produced by means of
organic chemical synthesis on solid phase [22].
2.5. ELISA test of immunogenic AF-16
The level of AF-16 in afﬁnity puriﬁed egg yolk was determined in an Enzyme-Linked Immunosor-
bent Assay (ELISA). The egg yolk samples were titrated in Maxisorp microtiter plates (Nunc) and
incubated overnight atþ4 C. After blockingwith 0.2% bovine serum albumin (BSA) in PBS for 45min at
37 C, the plates were washed with PBS þ 0.05% Tween 20. The polyclonal antibody aP8, raised against
the AF-16 peptide (see above), was thereafter added (diluted 1/500 in PBS þ 0.05% Tween 20 þ 0.2%
BSA), followed by 2 h incubation of the plates at room temperature. After washing, alkaline phosphate
(AP)-conjugated goat anti-rabbit immunoglobulin IgG (Jackson ImmunoResearch Europe Ltd.) was
added for 1 h at room temperature. After washing, the substrate 4-Nitrophenyl phosphate (Sigma-
eAldrich Sweden AB) in diethanolamine buffer (pH 9.8) with 1mMMgCl2, was added to the plates, and
the bound enzyme was registered by reading the absorbance at 405 nm. Rabbit pre-immune serum
was used as background. The pre-immune 405 absorbance values were subtracted from the sample
absorbance which resulted in net absorbance values.
2.6. Competitive enzyme immunoassay of AF-16 in egg yolk
A commercial AF-16 Enzyme Immunoassay (EIA) kit was used (BMA Biomedicals, Augst,
Switzerland). The laboratory procedure followed Protocol III in the enclosed Peptide EIA kit manual.
The standards S1-S6 (0.2e200 ng/ml) of AF-16 included in the kit, H-VCHSKTRSNPENNVGL-OH, was
serial diluted in EIA bufferþ 0.25% BSA. The standards or the afﬁnity puriﬁed egg yolk samples, i.e. eggs
collected before start of the feeding experiments, or eggs from hens treated for 5 weeks, 10 weeks or 18
weeks with AF-stimulating feed were added to the 96-well plate. This plate had been coated with
polyclonal antibodies against AF-16 diluted in EIA bufferþ 0.25% BSA. The samples were analyzed in
duplicates. After 1 h of incubation at room temperature, a dissolved biotinylated tracer was added for
2 h followed by 1 h incubation with streptavidin-HRP. The substrate was then added and the bound
enzyme developed. The reactions were terminated by adding 2 M HCl per well, where after the
absorbance was read at 450 nmwithin tenminutes. The concentration (ng/ml) of AF-16 was calculated
in the egg yolk samples after a standard curve was plotted of the 450 nm absorbance reading (minus
the absorbance values of the EIA buffer in the blank wells).
2.7. Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) analysis
Puriﬁed solutions of egg-yolk were prepared using afﬁnity-chromatography as described above. a-
Cyano-4-hydroxycinnamic acid (HCCA), triﬂuoroacetic acid (TFA) and acetonitrile (ACN) were all
purchased from Sigma Aldrich. Deionized water (18.4 MU) was prepared using a Millipore Milli-Q
system (Bedford, MA). Standard AF-16 peptide was purchased from Ross-Pedersen AS, Copenhagen.
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2,5% TFA) were mixed with one ml of the standard AF-16 peptide solution and the afﬁnity puriﬁed egg
yolk solutions, respectively. The mixtures were then vortexed, centrifuged and dropped onto the
MALDI ground steel plates and allowed to air dry.
All themass spectrometry data (mass range of 400e3000 Da) were acquiredwith an UltraﬂeXtreme
MALDI TOF/TOF Instrument (Bruker Daltonics GmbH) running in reﬂective positive (RP) mode at 1 kHz
laser repetition rate, and with the laser beam focus set to medium. The peptide calibration standard
mixture in a mass range between 1000 Da and 3500 Da were used to calibrate the spectra externally.
An autoXecute method in Flex control (v 3.0 Bruker, Daltonics GmbH, Germany) were used to collect
90,000 satisfactory laser shots in 300 shot steps from each spot on the MALDI MTP 384 ground steel BC
target plate with a hexagon raster movement. Flex analysis (v 3.0 Bruker, Daltonics GmbH, Germany)
and Origin (v. 8.1 OriginLab, Northampton, MA) were used for data analysis. Average spectra were
exported as ASCII ﬁle from Flex Analysis. Peak areas were then calculated using a Gaussian function in
nonlinear curve ﬁtting analysis mode.
2.8. Statistics
Graphs were constructed using Excel 2010. One-way Student's t-test was used for comparing mean
values in order to calculate the p values of signiﬁcance. Thus, statistics are presented using the mean
value ± SEM unless otherwise stated.
3. Results
3.1. Active AF in egg yolk tested in vivo by the rat ligated loop assay
Egg-yolk samples were tested for AF activity by means of the rat ligated loop assay. The eggs had
been collected each week from hens during their intake of an AF-stimulating diet. Each week three or
four rats were used for ligated loop test of afﬁnity puriﬁed AF prepared from four pooled egg yolks.
Thus, the AF activity tested represents the mean AF activity extracted from the four pooled egg yolks.
The values of AF activity presented in Table 1 represent values from the beginning, middle part and end
of the experiment, i. e. after a total of 18 weeks of feeding with the AF stimulating diet. The results in
Table 1 demonstrate stimulated AF activity for up to 14e18 weeks of diet intake. However, the
continuous increase of AF activity terminated after some 15 weeks, and in the period between 15 and
18 weeks no further stimulation of AF activity could be registered by the ligated loop assay. Conse-
quently, theweekly egg collection ended after 18weeks of AF stimulating feeding. In the yolk from eggs
collected during the last weeks of AF-stimulating feed intake, a signiﬁcant AF activity was determined
in samples diluted up to 1:1000 (Table 1).
3.2. ELISA for test of AF-activity in puriﬁed egg yolk
The results in Fig. 1 demonstrate increasing immunogenic AF-16 values in egg yolk samples ob-
tained from hens fed AF-stimulating feed for up to 18 weeks. The ELISA absorbance levels was low inTable 1
AF activity in puriﬁed egg-yolk samples collected from hens feeding an AF-inducing diet between 2 weeks and up to 18 weeks. A
value of >0.5 AF-units correlates to a signiﬁcantly inhibited intestinal secretion in response to cholera toxin challenge.
Test group Weeks of
AF-inducing diet
N AF-units means ± SEM* Puriﬁed egg yolk
dilution in test
A 2e3 6 0.2 ± 0.01 e
B 8e9 6 0.6 ± 0.02 e
C 14e18 8 0.5 ± 0.02 1:1000
 Signiﬁcance: A vs. B, P ¼ 0.0025.
 A vs. C, P ¼ 0.0123.
 B vs. C, P ¼ 0.001, (the sample was diluted 1:1000 before test).
Fig. 1. ELISA test by use of antibody aP8 in pooled (N ¼ 4) egg yolk samples prepared weekly during AF-stimulated feeding of the
hen.
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feeding. The continuous rise of immunogenic AF-16 values in response to feeding tentatively suggests
that the AF yolk values directly reﬂect the biological response of the hen to the AF-stimulating feed.
3.3. EIA for test of AF-activity in puriﬁed egg yolk
A commercial kit for determination of yolk AF-16 concentration demonstrates constant increase of
absorbance values over time (Fig. 2). After 10 weeks of AF-stimulating feed intake, the AF-16 con-
centration was four times higher when compared to 5 weeks (3 and 12 ng/ml, respectively), and after
18 weeks the AF-16 concentration demonstrated 24 ng/ml. The AF concentration in the egg yolk did
not, however increase in the period between 15 and 18 weeks of feeding.
3.4. Relative quantiﬁcation of AF-16 in puriﬁed egg yolk determined by MALDI-MS
MALDI-MSwas used for the relative quantiﬁcation of the AF-16 peptide in puriﬁed egg yolk samples
(Fig. 3). The autoXecutemethod showed an increasing normalized signal intensity in egg yolk collected
between 3 weeks and up to 18 weeks of AF-stimulating feed intake. Since HCCAwas used as the matrix
solution, the signal intensities of AF-16 were normalized to thematrix signal atm/z 568.2 [3HCCAþH].
The results in Fig. 3 demonstrate a more than threefold increase in AF-16 signal in the yolk samples
collected between 3 weeks and up to 18 weeks after intake of AF-stimulating feed.
The relative amount of AF-16 peptide in egg yolk was determined by means of a dilution series of
the AF-16 peptide added to puriﬁed egg yolk samples and followed by MALDI-MS analyses (Fig. 4).
Normalizing to the three different matrix signals all gave similar results. These results tentatively
suggest that this method is applicable to relative quantiﬁcation of the egg-yolk AF-16 peptides down to
ng/ml levels.
The AF-16 concentrations in puriﬁed egg yolk samples were determined by means of MALDI-MS
(Fig. 5). The numeric AF-16 values of concentration (ng/ml) were determined by comparing to the
values calculated in the standard curve demonstrated in Fig. 4. After 18 weeks of feeding, the AF-16
concentration could be determined to 1.5 ng/ml.
4. Discussion
A regulated intake of Salovum has been tested in controlled, clinical studies on patients suffering
from various diseases dominated by secretory imbalance and inﬂammation [8,14,15,23]. The clinical
inﬂuence of Salovum demonstrated on this broad variety of pathophysiology suggests a general,
modulating effect of actAF in the ﬁrst hand on neuronal tissue, but also on intestinal tissue [18].
Fig. 2. Competitive enzyme immunoassay of AF-16 concentration performed on puriﬁed egg yolk obtained from hens fed AF-
stimulating feed (N ¼ 4). The ng/ml concentrations values were determined by means of calculating AF-concentrations in the
standard curve.
Fig. 3. 90,000 satisfactory laser shots collected from each sample showing the average normalized signal intensity of the AF-16
peptide from pooled, puriﬁed egg yolk samples (N¼ 4) ranging from 3 weeks and up to 18 weeks after intake of AF stimulating
feed. The experiment was repeated 3 times and with similar results at each occasion.
I. Kaya et al. / Clinical Nutrition Experimental 12 (2017) 27e36 33Furthermore, improvement of the clinical outcome in response to Salovum treatment demonstrates
the need for a method capable of quantiﬁcation of the actAF concentration in Salovum. The validity of
such methods is of major relevance for a regulated patient treatment, in order to ensure constant and
reproducible effect on the clinical outcome over time on the diseased patient. Consequently, the AF
concentration in the egg yolk must be determined in each one of the Salovum batches produced.Fig. 4. MALDI-MS analysis of the relative amount of the AF-16 peptide in puriﬁed egg yolk samples (n ¼ 3).
Fig. 5. MALDI-MS analysis of the AF-16 concentration in puriﬁed egg yolk samples. The numeric values in ng/ml were determined by
comparing to the values calculated in the standard curve visualized in Fig. 4 (n ¼ 3).
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performed in vivo as well as in vitro. Thus, the rat ligated loop assay is performed in vivo, and the
secretory response to the challenging agent injected into the loop is registered without any interfer-
ence of anesthetic drugs. The absence of anesthetic drugs during the secretory response is of impor-
tance, sincemost forms of these drugs in various ways inﬂuences the transport of water and ions across
the cellular membrane. The intestinal secretory response to cholera toxin after intravenous injection of
afﬁnity puriﬁed egg yolk represent the net sum effect of all forms of antisecretory molecules present in
the yolk. Previous works demonstrate that almost all of such peptides emanates from the amino ter-
minal part of the AF protein [13]. However, antisecretory inﬂuence mediated by low concentrations of
other peptides than the AF-related peptides, cannot be excluded.
ELISA was used for test of immunogenic AF-16, which also includes related immunogenic mole-
cules, and the polyclonal antibody used in this test has been raised in rabbit.
After 18weeks of AF-stimulated feeding, quantiﬁcation usingMALDI-MS of the AF-16 concentration
in the egg yolk samples resulted in a calculated AF-16 concentration value of 1.5 ng/ml. This is in
contrast to the 24 ng/ml value achieved by use of the competitive immunoassay. The discrepancy
between these two concentration values might partly be explained by the immunological reactivity in
binding of AF antigens. Thus, such immunological cross reactivity will inevitably produce high ELISA
absorbance values. In contrast, theMALDI-MSmethod determines solely the exact AF-16 concentration
in the samples, due to the fact that these values are based on molecular weight data obtained by mass
spectrometry from repeated laser shots into the medium.
Quantitative analysis using the MALDI-MS technique has previously been viewed as very difﬁcult
[24]. This is based on the fact that the matrix crystallization seldom yields a uniform distribution of the
analyte and matrix on the analyzed target, resulting in regions with high and low signal intensity [25].
Thus, in the present experiments we therefore applied a standardized sample preparation protocol,
careful calibration, replicated measurements and normalization of the ion intensities to several
different matrix peak [24,26,27]. Thereby we achieved quantiﬁcation when comparing intensities to
known concentrations of AF-16 analyzed in the egg yolk medium. Consequently, we could create a
calibration curve for the real egg yolk samples.
Amongst the methods used for AF determinations in the present paper the MALDI-MS technique
must so far be considered as the most accurate technique for determination of the AF-16 concentra-
tions in the puriﬁed egg yolk samples. The in vivo rat ligated loop assay demonstrates the net sum of all
forms of peptides mediating antisecretory activity in the afﬁnity puriﬁed egg yolk. Consequently, the
effects achieved by this in vivo method also include antisecretory effects mediated by molecules not
related to AF, but also afﬁnity puriﬁed by the methods described. However, a similar form of signiﬁcant
increase of values over time in the 18 weeks long experimental feeding period was demonstrated by all
of the four methods used. Thus, low values were registered at the beginning of the feeding period,
while increasing values were registered for up to 15 weeks. Thereafter a plateau was reached with no
further increase achieved by any of the methods. Consequently, the ligated loop assay does serve as the
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intravenously. However, in clinical routine, the in vivo ligated loop assay cannot be used for AF de-
terminations due ethical reasons, performance difﬁculties, time and cost. Thus, all forms of AF analyses
in clinical work must be performed by means of in vitro methods.
The in vitromethods, however, all servewith a more limited, but more speciﬁc determination of the
antisecretory peptides.
Consequently, the observed correlation over time between the in vivo and in vitromethods strongly
suggests that the three in vitro methods all can be used for determination of anti-secretory and anti-
inﬂammatory potency of the future Salovum batches produced. Furthermore, the inhibited increase
of yolk actAF in response to feeding in the 15e18-week period suggests the existence of a “regulatory
feed-back” system for the interaction between plasma actAF concentration in relation to intestinal
stimulation of AF. This form of interaction needs further experiments to explain.
The presented methods for determination of AF concentrations in the afﬁnity puriﬁed egg yolk will,
when performed together, hopefully provide a more exact quantitative description of the actAF con-
centration and potency determined in the various Salovum batches to be produced. For the medical
doctor, a reproducible description of the yolk quality is a prerequisite for a documented, standardized
and repeatable treatment of the patient. Following tests of the clinical potency and effects of the
present batch of Salovum produced, has been performed. Thus, signiﬁcant reduction of pediatric
diarrhea has been documented from Lahore, Pakistan following oral Salovum treatment of the diseased
children (Prof. Shakila Zaman, pers. comm). In Sweden, oral Salovum© treatment of neonatal piglet
diarrhea signiﬁcantly inhibit diarrhea secretion, while at the same time eliminate death commonly
registered in relation to dehydration (dr. Leif G€oransson, pers. comm.)
However, there is still a need for a continuous development of reﬁned chemical analysis of the egg
yolk, preferably speciﬁcally pointing out the anti-secretory and anti-inﬂammatory potency. This work
must be continuously ongoing in order to ensure the Salovum-treated patient to reach an optimal
clinical outcome.
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